{rfName}
Ef

Indexed in

License and Use

Icono OpenAccess

Citations

37

Altmetrics

Analysis of institutional authors

Martin Pena, MerceAuthorMunoz-Cano, RCorresponding AuthorAinsua-Enrich, EAuthorMartin, MAuthorSanchez-Lopez, JAuthorBartra, JAuthorPicado, CAuthorMullol, JAuthorValero, AAuthor

Share

October 25, 2016
Publications
>
Article
Bronze

Effects of rupatadine on Platelet activating factor (PAF)-induced human mast cell degranulation compared with desloratadine and levocetirizine (The MASPAF study)

Publicated to: Journal Of Investigational Allergology And Clinical Immunology. 27 (3): 160-168 - 2017-01-01 27(3), DOI: 10.18176/jiaci.0117

Authors: Munoz-Cano, R; Ainsua-Enrich, E; Torres-Atencio, I; Martin, M; Sanchez-Lopez, J; Bartra, J; Picado, C; Mullol, J; Valero, A

Affiliations

Ctr Invest Biomed Red Enfermedades Resp CIBERES, Barcelona, Catalonia, Spain - Author
Hosp Clin Barcelona, Serv Otorinolaringol, Unitat Rinol & Clin Olfacte, Barcelona, Catalonia, Spain - Author
Hosp Clin Barcelona, Serv Pneumol & Allergia Resp, Unitat Allergia, Barcelona, Catalonia, Spain - Author
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Immunoallergia Resp Clin & Expt, Barcelona, Catalonia, Spain - Author
Univ Barcelona, Barcelona, Catalonia, Spain - Author
Univ Barcelona, Biochem Unit, Sch Med, Barcelona, Catalonia, Spain - Author
Univ Panama, Sch Med, Pharmacol Dep, Panama City, Panama - Author
See more

Abstract

Platelet-activating factor (PAF) is a lipid mediator involved in the pathophysiology of several allergic diseases, for example, in the ampli?cation of mast cell (MC) activation in anaphylaxis. Rupatadine is an antihistamine with a demonstrated anti-PAF effect, although its capacity to inhibit PAF-induced MC degranulation has not been fully evaluated. Objectives: To compare the ability of rupatadine to inhibit PAF-induced MC degranulation with that of desloratadine and levocetirizine and to confirm the dual anti-H1 and anti-PAF activity of rupatadine.The human MC line LAD2 and primary MCs (human lung tissue MCs [hLMCs]) were used. MC mediator release was evaluated using the b-hexosaminidase and histamine release assay. The effects of rupatadine (H1 antagonist + PAF receptor antagonist), desloratadine, and levocetirizine (H1 antagonists) on LAD2 and hLMCs were compared. The PAF receptor antagonists WEB2086, BN52021, and CV6209 were also tested. PAF receptor protein expression was evaluated in both LAD2 and hLMCs.CV6209 and rupatadine inhibited PAF-induced MC degranulation in both LAD2 and hLMCs. In LAD2, rupatadine (5 and 10 µM) and levocetirizine (5 µM), but not desloratadine, inhibited PAF-induced b-hexosaminidase release. Rupatadine (1-10 µM), levocetirizine (1-10 µM), and desloratadine (10 µM) inhibited PAF-induced histamine release. Rupatadine at 10 µM had an inhibitory effect on hLMC degranulation, but levocetirizine and desloratadine did not.This study shows that rupatadine and, to a lesser extent, levocetirizine, but not desloratadine, inhibit PAF-induced degranulation in both LAD2 and hLMCs. These findings support the dual antihistamine and anti-PAF effect of rupatadine in allergic disorders.

Keywords

anaphylaxiscv6209desloratadinedouble-blindfactor antagonistfactor receptorhistaminein-vitrolad2levocetirizinemast cellplatelet-activating factorreleaserupatadinesymptomsurticariaAllergic rhinitisAzepinesBeta-n-acetylhexosaminidasesCell degranulationCell lineCetirizineCv 6209Cv6209CyproheptadineDesloratadineFibrinolytic agentsGinkgolide bGinkgolidesHistamine h1 antagonistsHistamine h1 antagonists, non-sedatingHumansLactonesLad2LevocetirizineLoratadineMast cellMast cellsPlatelet activating factorPlatelet activating factor receptorPlatelet aggregation inhibitorsPlatelet membrane glycoproteinsPlatelet-activating factorPyridinium compoundsReceptors, g-protein-coupledRupatadineRupatadine.TriazolesWeb 2086

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Investigational Allergology And Clinical Immunology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2017, it was in position 67/155, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Immunology. Notably, the journal is positioned en el Cuartil Q3 para la agencia Scopus (SJR) en la categoría Immunology and Allergy.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-10:

  • WoS: 16
  • Scopus: 15
  • Europe PMC: 6

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-10:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 25.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 25 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Panama.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Muñoz Cano, Rosa Maria) and Last Author (Valero Santiago, Antonio).

the author responsible for correspondence tasks has been Muñoz Cano, Rosa Maria.

Awards linked to the item

This study was supported by a Sociedad Espanola de Alergia e Immunologia Clinica (SEAIC) grant, Ministerio de Economia y Competitividad-Carlos III Health Institute (FIS-PI09/1202), Spain and Grupo Uriach SA, Barcelona, Spain. RM-C was the recipient of the Rio Hortega Fellowship, Ministerio de Economia y Competitividad, Carlos III Health Institute, Spain.